News | September 16, 2014

Minneapolis Heart Institute Announces Its First Implant of Portico Aortic Heart Valve System

St. Jude Medical Portico TAVR System Minneapolis Heart Institute Implant Trial

September 16, 2014 — The Minneapolis Heart Institute Foundation (MHIF) announced its first implant of the Portico Re-sheathable Transcatheter Aortic Valve System, developed by St. Jude Medical. With this, MHIF became the first hospital in the Midwest and the third in the country to implant the Portico valve as part of the Portico Re-sheathable Transcatheter Aortic Valve System U.S. IDE Trial (PORTICO clinical trial).

The Portico heart valve is used during transcatheter aortic valve replacement (TAVR) procedures, during which the valve is delivered via a catheter through a transfemoral artery or alternative access point. This eliminates the need for invasive open-heart surgery. As such, the PORTICO trial is enrolling patients who are considered to have a high or an extreme surgical risk that has eliminated them from consideration for open-heart surgery.

The Portico valve is the first transcatheter aortic valve that can be completely resheathed (brought back into the delivery catheter), repositioned at the implant site, or retrieved after partial deployment and prior to final implantation. This helps to ensure accurate placement of the valve, ultimately simplifying the implant procedure and minimizing procedural risk for the patient. Further, the valve is positioned in the patient’s heart as it continues to beat, which alleviates the need for cardiopulmonary bypass.

MHIF, with its pursuits and commitment to the latest innovations in patient care, played an integral role in this development. Vibhu Kshettry, MHIF researcher and cardiovascular thoracic surgeon at Minneapolis Heart Institute at Abbott Northwestern Hospital (MHI), led efforts during this first implantation and described the Portico system as an “ongoing improvement in current percutaneous technology and a step forward in acute management of this high-risk population.” Wesley Pedersen, MHIF researcher and cardiologist at MHI, worked in conjunction with Kshettry on this first case and noted, “My preliminary experience with this system fills in several gaps not currently addressed in transcatheter treatment of aortic stenosis - those being ease of use, minimization of paravalvular leak, and need for permanent pacemaker.”

For more information: mplsheart.org

Related Content

First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
Overlay Init